Adam Lenart
      OUR PEOPLE

      Dr. Adam Lenart​

      PhD, master’s in Economic Sociology, master's in Information and Data Science

      Manager Population & Public Health Research

      Contact

      Adam is Manager Population & Public Health Research, where he is responsible for modeling and generation of real-world evidence (RWE) for the health impact of adult smokers switching to our smoke-free products. Besides supervising his highly qualified team of experts on modeling, he contributes to regulatory dossiers, provides project support to medical affairs, health economics, external affairs and IT, as well as acts as an expert on epidemiology, study planning, and RWE. ​

      Adam holds master’s degrees in Economic Sociology from Corvinus University of Budapest (Hungary) and Information and Data Science from UC Berkeley School of information (California, United States). He completed his PhD research at the Max Planck Institute of Demographic Research and earned a PhD from University of Rostock (Germany).  ​

      Early in his career he taught courses on biostatistics, mathematical demography, and programming and has published in high-ranking journals such as Nature, Aging Cell, Proceedings of the National Academy of Sciences, and Scandinavian Actuarial Journal. Later, he joined the pharmaceutical industry and focused on understanding real-world statistics with the aim of turning them into business or scientific insights. He is an experienced data scientist who has worked on business implementation of machine learning methods.  He has been working in multiple roles with a cross-functional reach across the whole manufacturing and pharmaceutical value chain starting with early research, clinical product development, regulatory submissions, scientific publishing, then ending with safety reporting, public messaging, and commercialization. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.